Abstract Book

S751

ESTRO 37

stage IV. Patients with Karnofsky performance status <80 had a worse survival (HR 1,65; CI 1,27-2,15, P<0.001). Stage III (HR 2,126; CI 1,156-3,909, P=0.015) and stage IV patients (HR 3,561; CI 1,817-6,977, P<0.001) had a worse survival than stage I-II. Patients who underwent surgery (HR 0,367; CI 0,226-0,595; P<0.001), pulmonary radiotherapy (HR 0,402; CI 0,286- 0,567; P<0.001), or chemotherapy (HR 0,453; CI 0,327-0,628; P<0.001) had lower risk of mortality. The median GHS, PF, RF, EF, CF, and SF scores were 67%, 80%, 33%, 75%, 100%, and 67%, respectively. Patients with higher scores for GHS (HR 0,59; CI 0.45-0.78; P<0.001), PF (HR 0.56; CI 0.43-0.73; P<0.001), EF (HR 0.58; CI 0.44-0.76; P<0.001) and SF (HR 0.65; CI 0.507-0.85; P<0.001) had a lower risk mortality. Multivariate analysis showed that those who had a worse stage had a higher risk of mortality (HR 1,53; CI 1,14- 2,05; P=0.004) while those who underwent surgery (HR 0,37; CI 0,22-0,62; P=0.000), received radiotherapy (HR 0,36; CI 0,25-0,51; P=0.000) or chemotherapy (HR 0,36; CI 0,25-0.52; P=0.000) had a lower risk. Additionally, patients with higher score in the emotional (HR 0,632; CI 0,47-0,85; P=0.002) and rol functioning (HR 0,62; CI 0,45-0,86; P=0.004) associated with lower risk of mortality. We observed that the HRQOL did not impact in survival in elderly patients (>70 years) with good KPS (≥80). However, when elderly patients had KPS < 80, the HRQOL, specifically in RF (HR 0,45; CI 0,25-0,8; P=0.007) and EF (HR 0,42; CI 0,22-0,78; P=0.007) impacted on survival, decreasing the mortality in those patients with higher scores. Conclusion Higher pre-radiotherapy HRQOL scores associates with lower mortality. We were able to find a subset of fragile patients (>70 years old with KPS <80) that may benefit from more radical treatments if they have a good quality of life.Promoting and improving QoL can positively impact in survival and this scoring could be added as prognostic factor to guide our treatment decisions. A. Otero-Romero 1 , I. Navarro-Domenech 1 , A. Román- Jobacho 1 , A. Pérez-Rozos 1 , A. Fernández-Forné 1 , R. Correa-Generoso 1 , R. Ordoñez-Marmolejo 1 , I. García- Ríos 1 , M. García-Anaya 1 , J. Gómez-Millán 1 , J. Medina- Carmona 1 1 Hospital Virgen de la Victoria, Oncología Radioterápica, Málaga, Spain Purpose or Objective To analyse the influence of clinical factors and comorbidity in Overall Survival (OS) and Disease free Survival (DFS) in patients with advanced NSCLC treated with radical radiotherapy and chemotherapy Material and Methods Retrospective analysis of 157 patients with advanced NSCLC treated with radical intention with either concomitant or sequential radiation-chemotherapy from 2005 to 2014 in our department. Age, performance status (ECOG), comorbidity, Haemoglobin at diagnosis, weight loss, histology, Stage, PET scan at diagnosis, PTV volume and timing of Radiotherapy (concomitant versus sequential) were analysed as prognostic factors. Comorbidity was assessed with a simplified score scale (SCS). Kaplan-Meier and multiple regression analysis were performed for statistical analysis. One patient was excluded from analysis due to loss of follow-up. Results 157 patients (138 men, 19 women), median age 64 years (34-83). ECOG0: 49%, ECOG1-2: 51%. SCS 0-7: 31.2%, SCS 8-9: 41.4%, SCS 10-11: 5.7%, SCS>=12: 21.7%. Haemoglobin (Hb) 6-16.9 gr/dl (median 13.4). Weight loss 0-40% (median 2.6%). Stage IIIA: 43.9%, IIIB: 56.1%. PET- scan yes: 28.6%, No PET scan: 41.4%. Squamous 58%, Adenocarcinoma 24.8%, undifferentiated 16.5%. PTV EP-1376 Prognostic factors for clinical outcome in advanced non-small-cell lung cancer (NSCLC)

volume from 92-1395 cc(median 580 cc). Concomitant radio-chemotherapy 75.2%, sequential 24.8%. Radiation DBE 70.1-88.8 (median 83.05). Acute toxicity present in 92.4%. Median follow up of 32 months (1.97-151 months), At time of analysis 82.7% of patients were dead ( 66% died from cancer, 16.7% died from other causes). Median OS 21.9 months and DFS 15.2 months. OS 2 years: 44.6%, 5 years 23.2%, 10 years 10.4%. DFS 2 years: 31.2%, 5 years 21.9%, 10 years 15.2% Independent prognostic factors for OS were: Weight loss >5% (p=0.003), age >70 years (p=0.03) and stage (p=0.004), and for DFS: Stage(p=0.03), Weight loss >5%(p=0.03) and PTV>600 cc (p=0.04). Patients with SCS>8 had more probability of dying from a non-cancer cause than those with lower morbidity (p: 0.02)

Conclusion Age, Haemoglobin, weight loss, stage and PTV volume were factors with significant poor outcome in our series. Age >70 years was associated with more comorbidities. Despite OS was the same independently the SCS score, the group of SCS >8 had more probability of dying from non-tumoral causes. EP-1377 Tolerability of radical lung hypofractionated radiotherapy in elderly patients A.M. Otero Romero 1 , I. Navarro-Domenech 1 , A. Fernández-Forné 1 , A. Román-Jobacho 1 , R. Correa- Generoso 1 , M. García-Anaya 1 , I. García Ríos 1 , R. Ordoñez- Marmolejo 1 , J. Gómez-Millán 1 , A. Pérez-Rozos 1 , J. Medina-Carmona 1 1 Virgen de la Victoria, Oncología Radioterápica, Málaga, Spain Purpose or Objective To analyse the influence of age and comorbidity in toxicity, overall survival (OS) and disease free survival (DFS) of hypofractionated radiotherapy (RT) in lung cancer. Material and Methods In our institution we have adopt the hypofractionated scheme of 55 Gy in 20 fractions (2.75 Gy per fraction) for